Oncimmune (LON:ONC) Trading Down 11.2% – Should You Sell?

Oncimmune Holdings plc (LON:ONC)’s share price traded down 11.2% during mid-day trading on Wednesday . The company traded as low as GBX 7.50 ($0.09) and last traded at GBX 7.70 ($0.10). 518,290 shares were traded during trading, an increase of 96% from the average session volume of 264,917 shares. The stock had previously closed at GBX 8.68 ($0.11).

Oncimmune Stock Performance

The company has a market cap of £6.10 million, a price-to-earnings ratio of -274.17 and a beta of 1.19. The company has a debt-to-equity ratio of 806.85, a current ratio of 1.13 and a quick ratio of 0.63. The firm has a fifty day simple moving average of GBX 13.37 and a 200 day simple moving average of GBX 14.80.

Oncimmune (LON:ONC) last posted its earnings results on Monday, February 10th. The company reported GBX (4.72) (($0.06)) earnings per share (EPS) for the quarter. Oncimmune had a net margin of 586.08% and a negative return on equity of 760.96%.

Oncimmune Company Profile

Oncimmune Holdings plc, an immunodiagnostics company, develops solutions for immuno-oncology, autoimmune disease and infectious diseases in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, an immunodiagnostic blood test for detecting and identifying lung cancer; ImmunoINSIGHTS that enables life science organizations to optimize drug development and delivery; SeroTag discovery arrays for discovering and validating biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel.